Intervention research for suicidal behaviour

Lancet

Volumn 362, Issue 9387, 2003, Pages 844-845

  Oquendo, Maria A ^a   Mann, J John ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

BIPOLAR DISORDER; BORDERLINE STATE; CLINICAL TRIAL; DEATH; DIAGNOSTIC PROCEDURE; HUMAN; MAJOR AFFECTIVE DISORDER; MAJOR DEPRESSION; MEDICAL RESEARCH; MEDICOLEGAL ASPECT; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; SAFETY; SCHIZOPHRENIA; SEIZURE; STATISTICAL MODEL; SUICIDAL BEHAVIOR; SUICIDE ATTEMPT; SYMPTOM; TYPES OF STUDY;

EID: 0141629867     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14347-4     Document Type: Note

References (14)

1. World Health Organization. Mental health. Prevention of suicical behaviours: a task for all. April 5, 2002: http://www5.who.int/mental_health/main.cfm?p=0000000140 (accessed June 30, 2003).
2. National Institute of Mental Health. Ethical issues in including suicidal individuals in clinical research. Workshop, Washington, DC, June 7-8, 2001: http://www.nimh.nih.gov/events/ethicsworkshop.cfm (accessed June 30, 2003).
3. Pearson J., Stanley B., King C.A., Fisher C.B. Intervention research with persons at high risk for suicidality: safety and ethical considerations. J Clin Psychiatry. 62:2001;17-26.
4. Montgomery S.A., Dunner D.L., Dunbar G.C. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol. 5:1995;5-13.
5. Rouillon F., Phillips R., Serrurier D., Ansart E., Gérard M.J. Rechutes de dépression unipolaire et efficacité de la maprotiline. L'Encéphale. XV:1989;527-534.
6. Filteau M.-J., Lapierre Y.D., Bakish D., Blanchard A. Reduction in suicidal ideation with SSRIs: a review of 459 depressed patients. J Psychiatr Neurosci. 18:1993;114-119.
7. Thies-Flechtner K., Müller-Oerlinghausen B., Seibert W., Walther A., Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorder. Pharmacopsychiatry. 29:1996;103-107.
8. Khan A., Warner H.A., Brown W.A. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 57:2000;311-317.
9. Storosum J.G., van Zwieten B.J., Wohlfarth T., de Haan L., Khan A., van den Brink W. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry. 60:2003;65-68.
10. Harkavy-Friedman J., Nelson E.A., Venarde D.F. Suicidal behavior in schizophrenia and schizoaffective disorder. Clin Neurosci Res. 1:2001;345-350.
11. Cornelius J.R., Salloum I.M., Lynch K., Clark D.B., Mann J.J. Treating the substance-abusing suicidal patient. Ann NY Acad Sci. 932:2001;78-93.
12. Kessler R.C., McGonagle K.A., Zhao S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 51:1994;8-19.
13. Kaufman K.R. Comparative bioethics in bipolar and epilepsy research. Seizure. 11:2002;51-56.
14. Post R.M., Luckenbaugh D.A. Unique design issues in clinical trials of patients with bipolar affective disorder. J Psychiat Res. 37:2003;61-73.